{"nctId":"NCT04698525","briefTitle":"Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.","startDateStruct":{"date":"2019-02-15","type":"ACTUAL"},"conditions":["Migraine Headache"],"count":33,"armGroups":[{"label":"Valproate group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Valproate Sodium"]},{"label":"Memantine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Memantine"]}],"interventions":[{"name":"Valproate Sodium","otherNames":["Diwali"]},{"name":"Memantine","otherNames":["Ezagun"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women from 18 to 65 years old.\n2. Diagnosis of migraine according to the ICHD-III of the IHS at least one year before the study.\n3. You must have at least 4-14 migraine attacks per month.\n4. Not receiving prophylactic treatment for migraine\n5. Sign informed consent\n\nExclusion Criteria:\n\n1. Pregnant or lactating patients.\n2. Patients with another type of non-migraine headache.\n3. Allergy to Sodium Valproate and/or Memantine\n4. Being a carrier of systemic disease (infectious, immunological, or metabolic processes) or cardiovascular (myocardial, coronary, or valvular disease) prevents their participation in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Days of Headache Pain With Treatment of Memantine or Valproate in the Preventive Management of Episodic Migraine.","description":"In a double-blind clinical trial, we compared two active drugs (mamantine vs. valproate) three months after initiation, looking for changes in the average number of days of migraine attack presentation per month and comparing the three months before with the three months after treatment administration with two active drugs.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.35","spread":"1.11"},{"groupId":"OG001","value":"5.31","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"1.16"},{"groupId":"OG001","value":"0.93","spread":"1.4"}]}]}]},{"type":"PRIMARY","title":"The Change in the Intensity of the Pain in a Migraine Attack Will be Measured by a Visual Analogue Scale (VAS).","description":"The possible reduction in the average on the visual analog scale (0-10) comparing three months before and after three months of the treatment with both drugs. We measured both arms of the study.\n\n0 means without pain. 10 means the worst possible pain in the concept of the patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.94","spread":"0.87"},{"groupId":"OG001","value":"8.5","spread":"1.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.87"},{"groupId":"OG001","value":"4.28","spread":"3.65"}]}]}]},{"type":"PRIMARY","title":"The Migraine Disability Assessment MIDAS Scale Will Measure Before and After the Treatment to Improve the Quality of Life in Both Groups After Three Months of Treatment.","description":"To compare the average of Memantine against the group that receives Valproate before and after starting preventive treatment. Using the Migraine Disability Assessment scale (The score is the sum of days missed from work or school, days of housework missed, days of missed non-work activities, and days of work or school plus days of housework in which productivity in the last three months) to compare punctuation changes. The MIDAS score is divided into four degrees, the minimum score is 0 points, and the maximum score is 70. A higher value represents a higher difficulty to carry out a satisfactory lifestyle, and a score higher than 20 points already represents a high limitation to enjoying daily activities:\n\nGrade I (0-5 points): Slight limitations and few patient treatment needs. Grade II (6-10 points): Moderate limitations and treatment needs. Grade III (11-20 points) and IV (21 or more points): Severe and significant punctuation treatment needs.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.92","spread":"22.67"},{"groupId":"OG001","value":"60.87","spread":"15.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.53","spread":"19.97"},{"groupId":"OG001","value":"15.57","spread":"14.3"}]}]}]},{"type":"SECONDARY","title":"Measure Changes in Weight With the Administration of Active Drugs.","description":"To compare the average weight in both arms before and after Valproate and Memantine administration. The weight will be measured in kilograms, and the initial against the final will be compared.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.77","spread":"10.3"},{"groupId":"OG001","value":"64.44","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.13","spread":"10.5"},{"groupId":"OG001","value":"64.19","spread":"5.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"To Compare the Adverse Events in the Use of Memantine in Comparision With Valpoate in the Episodic Migraine Treatment.","description":"The number of adverse events and the safety of memantine and valproate. Evaluated according to CTCAE v5.0. There were several side effects, but no one had life-threatening or serious side effects.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":17},"commonTop":["Somnolence","Lack of concentration","dizziness","Parasomnia"]}}}